Health Trials

Moderately To Severely Active Ulcerative Colitis

3

Review clinical trials related to Moderately To Severely Active Ulcerative Colitis. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with Afimkibart (RO7790121) compared with placebo in participants with moderately to severely active ulcerative colitis (UC).

Participants needed: 350
Trial details
Phase: Phase 3Age: 16-80Biological sex: AllType: InterventionalSponsor: Hoffmann-La RocheUpdated: Jul 2, 2026Locations: 200
Eligibility criteria

Confirmed diagnosis of UC [+5]

Currently known complications of UC (e.g. fulminant colitis, toxic megacolon) [+9]

Read more
Status: Recruiting

A Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis

This Phase III, randomized, double-blind, multicenter, induction and maintenance study will evaluate the safety and efficacy of Afimkibart (RO7790121) in pediatric participants with moderate to severe active ulcerative colitis (UC).

Participants needed: 100
Trial details
Phase: Phase 3Age: 2-17Biological sex: AllType: InterventionalSponsor: Hoffmann-La RocheUpdated: Jun 23, 2026Locations: 12
Eligibility criteria

Bodyweight >= 10 kilogram (kg) [+2]

Monogenic disorder pertaining to infant onset inflammatory bowel disease (IBD) [+5]

Read more
Status: Recruiting

A Phase 2 Study of D-2570 in Subjects With Moderately to Severely Active Ulcerative Colitis

This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The target population is patients with moderately to severely active ulcerative colitis. A total of 120 subjects are planned to be included.

Participants needed: 120
Trial details
Phase: Phase 2Age: 18-70Biological sex: AllType: InterventionalSponsor: InventisBio Co., LtdUpdated: Jun 24, 2025Locations: 1
Eligibility criteria

Subjects voluntarily take part in the study after being fully informed, sign a w... [+6]

Diagnosed or suspected Crohn's disease, indeterminate colitis, fulminant colitis... [+9]

Read more